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Abstract 30 
Importance: The World Health Organization (WHO) 2016–2020 Global Leprosy Strategy aims to 31 
reinvigorate efforts to control leprosy and avert leprosy disability to less than one per million 32 
population.  33 
Objective: This study aimed to identify systematically clinical factors associated with physical 34 
disability in patients with leprosy.   35 
Data source: Searches were performed in Scopus, PubMed and Web of Science databases to 36 
identify studies published up to May 2018, using the keywords leprosy and physical disability 37 
and related terms. 38 
Study selection: We included studies that evaluated patients using the WHO leprosy disability 39 
grading and reported the number of patients with and without disability by clinical 40 
characteristics. 41 
Data Extraction and Synthesis: The study was conducted following the Meta-Analysis of 42 
Observational Studies in Epidemiology (MOOSE) statement. We used the odds ratio (OR) as a 43 
measure of association between the clinical features and physical disability. Summary estimates 44 
were calculated using random-effects models. 45 
Main Outcome(s) and Measure(s): Our primary outcome was physical disability according the 46 
WHO disability classification. We evaluated the association between clinical features and 47 
physical disability. 48 
Results: Thirty-two studies were included in the systematic review. Males were more likely to 49 
have physical disability than females (pooled OR: 1.66; CI95% 1.43-1.93). Multibacillary (MB) 50 
leprosy were 4-fold more likely to have physical disability than paucibacillary (PB) leprosy 51 
 4 
patients (pooled OR 4.32; CI95% 3.37-5.53). Patients having leprosy reactions were more likely 52 
to have disability (pooled OR 2.43, CI95% 1.35-4.36). Patients with lepromatous leprosy 53 
experienced 5- to 12-fold higher odds of disability.  54 
Conclusion and Relevance: This systematic review and meta-analysis confirms the strong 55 
association between the presence of physical disabilities and male gender, MB leprosy, leprosy 56 
reactions and lepromatous presentation. These findings can guide the development of targeted 57 
interventions to identify early individuals at greater risk of developing physical disabilities and 58 
education campaigns to promote early consultation to institute treatment for leprosy reactions 59 
and to prevent physical disability. 60 
 61 
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Key points 65 
Question: What are the risk factors for physical disability in patients with leprosy? 66 
Findings: This systematic review and meta-analysis found a strong association between the 67 
presence of physical disabilities and male gender, MB leprosy, leprosy reactions and 68 
lepromatous presentation. 69 
Meaning: Our findings can guide the early identification of individuals at higher risk of 70 
developing physical disabilities and the development of targeted preventive interventions. 71 
72 
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Introduction 73 
Leprosy is a chronic infectious disease caused by Mycobacterium leprae that affects the skin 74 
and peripheral nerves leading to progressive physical disability and deformities if not diagnosed 75 
and treated early.1–3 Despite a significant reduction in its global prevalence since the World 76 
Health Organization (WHO) implemented the free multidrug therapy program in 1995, leprosy 77 
remains a major cause of morbidity due to its associated long term disabilities and sequelae4 78 
affecting an estimated two million people worldwide.5,6  79 
The WHO target is to reduce leprosy disabilities to less than one per million population through 80 
the strengthening of strategies for the prevention and reduction of deformities.7 These 81 
strategies include the early recognition and prioritization of individuals with characteristics 82 
associated with physical disability and the main focus of control programs and rehabilitation 83 
centers is to prevent and manage physical impairment to improve quality of life.8,9 Although 84 
clinical features such as multibacillary (MB) leprosy and leprosy reactions are considered to 85 
predispose to physical disability and deformity,2,5,10–13 there are no systematic analyses 86 
assessing the strength of this evidence. We report here a systematic review and meta-analysis 87 
to assess the clinical factors associated with physical disability in leprosy.  88 
Methods 89 
This study was conducted following the Meta-Analysis of Observational Studies in Epidemiology 90 
(MOOSE) statement.14 Institutional review board approval and informed consent were not 91 
required as all data were obtained from secondary data sources without identifiers. The study 92 
protocol was designed a priori and registered in the PROSPERO database (registration number 93 
CRD 42019118122). 94 
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Search strategy and selection criteria 95 
We systematically searched the PubMed, Scopus and Web of Science databases to identify 96 
studies published up to May 2018, using the keywords leprosy and physical disability and 97 
related terms, as described in eTable 1 of the supplement. Two independent reviewers (HLP 98 
and CDFS) screened the search results and identified potentially relevant studies based on their 99 
title and abstract. The studies were then read in full for consideration for inclusion in the 100 
analysis. Disagreements between the two reviewers were resolved by discussion. Studies were 101 
included if a) patients had been assessed for physical disability using the WHO leprosy disability 102 
grading1; b) the study evaluated the association between the clinical presentation and physical 103 
disability; and c) the clinical factors (exposure) were described according to the presence or 104 
absence of physical disability. We excluded publications without original data such as reviews 105 
and opinions, those with overlapping data or when data extraction was not possible. The 106 
authors of the latter studies were asked to provide access to the original databases, but none of 107 
them responded.  108 
We considered age, sex, clinical presentation categories, the presence of leprosy reactions and 109 
the WHO leprosy classification stage as exposure factors. The WHO classification includes 110 
paucibacillary (PB, ≤5 skin lesions and/or only one affected nerve trunk) and multibacillary (MB, 111 
>5 skin lesions and/or more than one affected nerve trunk) leprosy or based on smear 112 
microscopy findings into PB leprosy, if smear negative, or MB leprosy, if smear positive.15 113 
Clinical forms include tuberculoid, borderline or lepromatous and indeterminate 114 
presentations.16 Leprosy reactions include episodes characterized by the acute inflammation of 115 
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skin lesions or nerves (type 1) and/or the appearance of inflamed cutaneous nodules with or 116 
without neuritis (type 2).17 117 
Our primary outcome was physical disability according to the WHO disability classification.1 In 118 
this classification, grade 0 indicates no sensory impairment or disability/damage of the eyes, 119 
hands or feet; grade 1 indicates the presence of eye (vision >6/60) or sensory impairment in the 120 
hands or feet, without visible deformities or damages; grade 2 indicates severe visual 121 
impairment (vision  <6/60 or inability to count fingers at six meters) or the presence of visible 122 
deformity in the eyes (lagophthalmos, iridocyclitis and corneal opacities) or visible deformity or 123 
damage on hands or feet (ulcerations, traumatic injuries, resorption, claw, fallen hand, foot 124 
drop, ankle contracture). We combined physical disability grades 1 and 2 and considered them 125 
jointly for statistical purposes. 126 
Data extraction and bias assessment 127 
Data were extracted using standardized tables, including author, country, study design, 128 
participants characteristics, clinical setting (specialized health center, general hospital, primary 129 
health care or data obtained from a health information system) and physical disability 130 
(presence or absence). We extracted the number of cases with and without physical disability 131 
at the time of diagnosis and stratified for each exposure variable. Not all studies reported all 132 
variables and we used percentages to obtain the absolute number of patients by stratum. 133 
The Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies of the USA 134 
National Institutes of Health (https://www.nhlbi.nih.gov/health-topics/study-quality-135 
assessment-tools) was used to grade the quality of each study. Disagreements were resolved by 136 
discussion. 137 
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Statistical analysis 138 
We calculated the pooled odds ratio (OR) for the primary outcome and forest plots to present 139 
results with 95% confidence intervals (95% CI). Not all studies reported data on all exposure 140 
variables and the pooled OR was estimated from the data available for each variable. Pooled 141 
estimates were calculated using a random-effects model (DerSimonian and Laird method). Two-142 
tailed p-values <0.05 were used to determine statistical significance. Statistical heterogeneity 143 
was assessed using the Cochran’s Q test18 and quantified by the I2 index.19 144 
Subgroup analysis were performed according to the study design, population characteristics 145 
(adults, adults/children and children) and study setting. Publication bias was assessed by 146 
visually inspecting whether larger and smaller studies were asymmetrically distributed in the 147 
funnel plot.20 Leave-one-out sensitivity analysis was conducted to examine the influence of 148 
each study on the pooled effect size.21 Analyses were performed using STATA 14.0 (STATA 149 
Corp., College Station, TX, USA) and Review Manager 5.3 (Cochrane IMS, Copenhagen, 150 
Denmark). 151 
Results 152 
The search strategy identified 2,447 reports. After screening titles and abstracts, 177 full-text 153 
articles were assessed for eligibility and 32 were included in the analysis (Figure 1). Table 1 154 
describes the characteristics of the studies included. Most studies were cross-sectional (27, 155 
84.4%), four (12.5%) were from surveillance systems (continuous and routine reporting of cases 156 
for monitoring purposes) and only one (3.1%) was a cohort. Nine (28.1%) studies included 157 
adults, three (9.4%) included children and 20 (62.5%) enrolled both adults and children and 158 
reported them combined. Eleven (34.4%) studies were based in general hospitals, nine (28.1%) 159 
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in primary health care settings and eight (25.0%) in specialized health care centers, while four 160 
(12.5%) were data extracted from health information systems and the origin of the patients was 161 
not reported.  162 
The risk of bias of the studies is showed in eTable 2 in the supplement. All studies had clear 163 
objectives and eligibility criteria, recruited subjects from the same population and described 164 
the definitions of exposure factors and outcomes. However, most studies did not report the 165 
number of eligible participants recruited into the study. Since most studies were cross-166 
sectional, the exposure and outcome status (physical disability) of the participants were 167 
collected at the same time, which are potential sources of bias. 168 
Twenty-four studies had sex information (39,571 patients), of which 24,218 (61.2%) were male 169 
and 15,353 (38.8%) female.2,5,10–13, 22–38 Males were more likely to have physical disability than 170 
females (pooled OR: 1.66; 95% CI: 1.43-1.93; I2: 81.3%, P: <0.001) and the odds of physical 171 
disability did not depend on the study location (Figure 2). 172 
WHO leprosy classification data were obtained from 28 studies including 39,192 173 
patients.2,5,10,11,13,22,23,25–29,31–35,37–47  PB leprosy was more frequent than MB leprosy [25,954 174 
(66.2%) and 13,238 (33.8%), respectively], but patients with MB leprosy were 4-fold more likely 175 
to have physical disabilities (pooled OR: 4.32; 95% CI: 3.37-5.53; I2: 88.9%, P: <0.001) 176 
independently of the study location (Figure 3). 177 
Six studies reported leprosy reactions and disability,2,11,37,38,42,43 including 9,691 patients, of 178 
whom 1,694 (17.5%) had leprosy reactions and 7,997 (82.5%) no reactions, resulting a pooled 179 
OR of 2.43 (95% CI: 1.35-4.36; I2: 92.1%, P: <0.001) (Figure 4). The clinical presentation was 180 
reported in seven studies. Patients with lepromatous forms were more likely to have disability 181 
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than patients with borderline (pooled OR: 2.94, 95% CI: 1.72-5.02; I2: 92.2%, P: <0.001), 182 
tuberculoid (pooled OR: 5.85, 95% CI: 3.56-9.61; I2: 90.8%, P: <0.001) or indeterminate leprosy 183 
(pooled OR: 12.53, 95% CI: 6.34-24.76; I2: 86.4%, P: <0.001) and these pooled ORs were not 184 
dependent on the study location (Figure 5). 185 
Sensitivity analysis suggested the pooled ORs were stable and not obviously changed by a single 186 
study. No evidence of publications bias was observed (see eFigures 7-11 in the Supplement).  187 
Discussion 188 
Factors predisposing to the development of physical disability in leprosy have been reported 189 
extensively, providing an excellent opportunity for a comprehensive analysis. This review 190 
confirms that male patients, those with MB leprosy, leprosy reactions and lepromatous 191 
presentations are more likely to have physical disabilities.  192 
Men were almost 2-times more likely to have physical disability than women. This gender 193 
difference has been attributed to social behaviors and reluctance and difficulties in accessing 194 
health services.48 Men often ignore leprosy symptoms and seek health services at more 195 
advanced stages of the disease and with more severe clinical manifestations.49–51 Health 196 
professionals should be aware of their increased risk during active case finding activities and 197 
contact tracing, to ensure male contacts and secondary cases are not missed during home 198 
visits. 199 
Leprosy disease progression is determined by the cellular immune responses to M. 200 
leprae, which are expressed through different pathophysiological mechanisms. The absence of 201 
cellular and enhanced humoral immune responses of patients with MB leprosy are associated 202 
with high bacilli loads and result in neuritis and peripheral nerve damage.26,52 Patients with MB 203 
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leprosy in this review were more likely to have physical disabilities, highlighting the importance 204 
of good clinical classification and the smear microscopy detection of bacilli.16  205 
Although tuberculoid and indeterminate leprosy are the most frequent clinical presentations, 206 
our meta-analysis demonstrates that patients with lepromatous leprosy have 5- to 12-fold 207 
higher odds of disability. Lepromatous leprosy is characterized by T helper cell 2 immune 208 
responses with increased production of IL-4 and IL-10 and activation of regulatory T cells, a 209 
robust, but ineffective, production of antibodies with formation of immune complexes, and a 210 
failure to restrict M. leprae growth, especially into the Schwann cells.53 The immunological 211 
events triggered against infected Schwann cells then results in nerve injuries and consequent 212 
physical disability.54  213 
Individuals with leprosy reactions are more prone to peripheral nerve injuries and sequelae. 214 
Type 1 reactions are a reversal or upgrade of the cell-mediated immunity to M. leprae 215 
antibodies, while type 2 reactions are the result of immune complexes attracting granulocytes 216 
and activation of complement  and cytokine responses.53 Both reactions may damage 217 
peripheral nerves with impairment of function and can occur at any time in the clinical course 218 
of the disease, independently of treatment. It is thus recommended to follow leprosy cases for 219 
several years after  an apparently successful treatment.4,55,56  220 
This systematic review focused on the likelihood of disability among patients with leprosy 221 
reactions at the time of diagnosis. However, studies have reported a high risk of leprosy 222 
reactions after completion of MDT treatment, requiring long-term follow-up with repeated 223 
neurological examinations.4,10,57 The early identification of reactions and their prompt 224 
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management with prednisone (1 to 2 mg/kg/day for ≥90 days) can prevent neuropathies and 225 
disability.17 226 
The Global Leprosy Strategy 2010-2020 aims to accelerate action towards a leprosy-free world, 227 
with a focus on the early detection of cases, before disabilities occur, and the prevention and 228 
early detection of disabilities among higher risk groups by conducting active cases finding 229 
campaigns in highly endemic areas or communities.7 In this sense, our findings provide 230 
information to stakeholders regarding to the characterization of high risk patients that should 231 
be prioritized and targeted to receive preventive interventions for the early detection and 232 
reduction of grade 2 disability in endemic areas.  233 
Our findings however should be interpreted with caution. All studies included were 234 
observational and patients were not randomized and were often conducted with other primary 235 
objectives and therefore the studies are prone to patient selection bias and the disability 236 
information may not have been collected systematically. Moreover, it was not possible to 237 
perform meta-analyses to explore whether age, schooling level and socioeconomic status were 238 
associated with physical disability. Most studies, however, indicated the prevalence of disability 239 
increases with age and that disability is inversely proportional to socioeconomic conditions and 240 
educational level. Education and income are considered determining factors for disease 241 
improvement and protective for the occurrence of disability.2  242 
Despite these limitations, we demonstrate a strong association between the presence of 243 
physical disabilities and gender, MB leprosy, leprosy reactions and a lepromatous presentation. 244 
These findings can guide the development of targeted interventions to identify early individuals 245 
at risk of physical disabilities and to inform education campaigns promoting early consultation 246 
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to institute treatment for leprosy reactions and prevention of further physical disability. Long-247 
term follow-up is necessary to monitor factors associated with disabilities, and the provision of 248 
interventions promoting self-care, disability prevention and availability of rehabilitation 249 
services. 250 
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Table 1. Characteristics of the included studies. 445 
Study Country Study design Population Settings 
Risk factors 
analyzed 
Outcome 
Sample 
size 
Total 
disability 
Zhang et al, 1993 China 
Cross 
sectional 
Adults/ 
children 
Tertiary 
Health 
Centre 
Sex, WHO leprosy 
classification and 
clinical forms 
Combined 
grades 1 and 2 
14257 8122 
Tiendrebeogo et al, 1996 
Burkina 
Faso 
Cross 
sectional 
Adults 
Primary 
care 
Sex and WHO 
leprosy 
classification 
Combined 
grades 1 and 2 
554 165 
Çakiner et al, 1997 Turkey 
Cross 
sectional 
Adults Hospital Sex 
Combined 
grades 1 and 2 
711 546 
Wittenhorst et al, 1998 Zimbabwe Surveillance 
Adults/ 
children 
Information 
system 
Sex and WHO 
leprosy 
classification 
Grade 2 746 247 
Croft et al, 1999 Bangladesh 
Cross 
sectional 
Adults/ 
children 
Tertiary 
Health 
Centre 
Sex and WHO 
leprosy 
classification 
Combined 
grades 1 and 2 
2664 415 
Ahmad et al, 2004 Pakistan 
Cross 
sectional 
Adults Hospital 
Sex, WHO leprosy 
classification and 
clinical forms 
Combined 
grades 1 and 2 
100 41 
 Kar et al, 2005 India 
Cross 
sectional 
Children 
Tertiary 
Health 
Centre 
Sex, WHO leprosy 
classification and 
leprosy reaction 
Grade 2 275 29 
Rad, 2007 Iran 
Cross 
sectional 
Adults/ 
children 
Hospital 
Sex and WHO 
leprosy 
classification 
Combined 
grades 1 and 2 
180 79 
Silva-Sobrinho et al, 2007 Brazil 
Cross 
sectional 
Adults/ 
children 
Primary 
care 
Sex 
Combined 
grades 1 and 2 
99 79 
Lana et al, 2008 Brazil Surveillance 
Adults/ 
children 
Information 
system 
Sex and WHO 
leprosy 
classification 
Combined 
grades 1 and 2 
1461 672 
Soomro et al, 2008 Pakistan 
Cross 
sectional 
Adults Hospital 
WHO leprosy 
classification 
Separately 
grades 1 and 2 
100 55 
Ramos et al, 2010 Brazil 
Cross 
sectional 
Adults 
Tertiary 
Health 
Centre 
Sex and WHO 
leprosy 
classification 
Separately 
grades 1 and 2 
193 51 
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El-Dawela et al, 2012 Egypt 
Cross 
sectional 
Adults/ 
children 
Hospital 
WHO leprosy 
classification 
Grade 2 587 204 
Sarkar et al,2012 India 
Cross 
sectional 
Adults Hospital 
WHO leprosy 
classification 
Separately 
grades 1 and 2 
244 244 
Kumar et al, 2012 India Cohort 
Adults/ 
children 
Tertiary 
Health 
Centre 
Sex, WHO leprosy 
classification and 
clinical forms 
Grade 2 293 27 
Nardi et al, 2012 Brazil 
Cross 
sectional 
Adults/ 
children 
Primary 
care 
Sex, WHO leprosy 
classification and 
clinical forms 
Separately 
grades 1 and 2 
335 71 
van Brakel et al, 2012 Indonesia 
Cross 
sectional 
Adults 
Primary 
care 
Sex and WHO 
leprosy 
classification 
Separately 
grades 1 and 2 
1308 1003 
Monteiro et al, 2013 Brazil 
Cross 
sectional 
Adults/ 
children 
Primary 
care 
WHO leprosy 
classification and 
leprosy reaction 
Separately 
grades 1 and 2 
282 44 
Oliveira et al, 2013 Brazil 
Cross 
sectional 
Adults/ 
children 
Tertiary 
Health 
Centre 
Sex 
Separately 
grades 1 and 2 
494 142 
Guerrero et al, 2013 Colombia 
Cross 
sectional 
Adults/ 
children 
Primary 
care 
Sex and WHO 
leprosy 
classification 
Combined 
grades 1 and 2 
333 117 
de Castro et al, 2014 Brazil 
Cross 
sectional 
Adults 
Primary 
care 
Sex and WHO 
leprosy 
classification 
Combined 
grades 1 and 2 
225 137 
Silva et al, 2015 Brazil 
Cross 
sectional 
Adults/ 
children 
Primary 
care 
Sex and WHO 
leprosy 
classification 
Grade 2 1916 366 
Monteiro et al, 2015 Brazil Surveillance 
Adults/ 
children 
Information 
system 
Sex, WHO leprosy 
classification, 
leprosy reaction 
and clinical forms 
Grade 2 12328 664 
Santos et al, 2015 Brazil Surveillance 
Adults/ 
children 
Information 
system 
Sex, WHO leprosy 
classification, 
leprosy reaction 
and clinical forms 
Combined 
grades 1 and 2 
2358 656 
Sethi et al, 2015 India Cross Children Hospital WHO leprosy Separately 94 32 
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sectional classification and 
clinical forms 
grades 1 and 2 
Patel et al, 2016 India 
Cross 
sectional 
Adults 
Tertiary 
Health 
Centre 
Sex, WHO leprosy 
classification and 
leprosy reaction 
Separately 
grades 1 and 2 
239 127 
Onyeonoro et al, 2016 India 
Cross 
sectional 
Adults/ 
children 
Hospital 
Sex and WHO 
leprosy 
classification 
Separately 
grades 1 and 2 
287 168 
Queirós et al, 2016 Brazil 
Cross 
sectional 
Adults/ 
children 
Hospital 
WHO leprosy 
classification 
Separately 
grades 1 and 2 
458 63 
Anjum et al, 2017 India 
Cross 
sectional 
Adults/ 
children 
Tertiary 
Health 
Centre 
WHO leprosy 
classification 
Combined 
grades 1 and 2 
54 48 
Rodrigues et al, 2017 Brazil 
Cross 
sectional 
Adults/ 
children 
Hospital 
Sex and WHO 
leprosy 
classification 
Combined 
grades 1 and 2 
182 124 
Darlong et al, 2017 India 
Cross 
sectional 
Children Hospital 
WHO leprosy 
classification 
Grade 2 319 21 
Haefner et al, 2017 Brazil 
Cross 
sectional 
Adults/ 
children 
Primary 
care 
Sex 
Separately 
grades 1 and 2 
910 262 
 446 
 447 
 448 
 449 
 450 
 
 2447 Records identified through 
database searching 
0 Additional records identified 
through other sources 
 
1493 Records after duplicates removed 
267 Records screened 
122 Records excluded 
145 Full-text articles assessed for eligibility 
113 Full-text articles excluded 
 
73 No relevance 
32 No extractable data 
  4 Overlap of population 
  4 Reviews 
32 Studies included in meta-analysis 
NOTE: Weights are from random effects analysis
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Study
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59/66
1390/2884
490/5469
78/200
397/745
32/94
93/240
79/146
4297/15353
13/112
811/6618
Female
33/121
4/104
20/64
70/125
2094/3901
50/57
80/140
145/184
92/350
9/30
2372/5663
Events,
32/115
270/1196
85/432
142/925
304/475
356/486
130/1183
20/33
810/2597
174/4361
64/195
275/711
19/75
72/360
48/93
100.00
2.43
23.46
Weight
3.96
1.49
3.04
3.58
6.62
1.28
4.20
4.52
5.22
1.95
27.49
%
3.45
6.12
5.30
5.78
14.98
5.60
5.86
1.58
34.08
6.15
4.48
5.96
2.88
4.82
3.74
Favors Female  Favors Male 
1.0639 15.6
NOTE: Weights are from random effects analysis
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Kumar et al, 2012
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Sarkar et al,2012
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Subtotal  (I-squared = 76.9%, p = 0.000)
Primary health care
Subtotal  (I-squared = 97.7%, p = 0.000)
Soomro et al, 2008
El-Dawela et al, 2012
Santos et al, 2015
Darlong et al, 2017
Kar et al, 2005
Specialized health center
General hospital
4.32 (3.37, 5.53)
0.54 (0.07, 4.40)
2.32 (1.38, 3.91)
5.61 (2.22, 14.21)
2.35 (1.03, 5.35)
1.41 (1.04, 1.92)
8.52 (6.95, 10.45)
5.68 (3.16, 10.20)
4.84 (2.38, 9.86)
1.11 (0.66, 1.86)
11.94 (5.10, 27.92)
7.98 (6.31, 10.08)
6.04 (2.90, 12.58)
13.93 (10.01, 19.38)
3.81 (3.39, 4.29)
15.00 (1.17, 191.55)
3.97 (1.42, 11.11)
13.87 (4.13, 46.57)
OR (95% CI)
4.33 (2.69, 6.95)
4.74 (3.07, 7.31)
7.45 (5.68, 9.78)
4.15 (2.07, 8.33)
2.34 (1.24, 4.40)
3.20 (1.99, 5.16)
2.04 (0.86, 4.84)
3.85 (2.31, 6.42)
4.21 (2.87, 6.17)
5.21 (2.32, 11.74)
2.58 (0.90, 7.39)
5.67 (2.00, 16.10)
4.42 (3.64, 5.37)
6.04 (1.74, 20.90)
3.50 (1.45, 8.44)
5748/13238
106/117
92/222
33/58
111/126
138/377
547/3794
98/125
34/70
78/144
97/311
203/444
33/112
626/1013
1610/1984
Events,
45/51
17/125
145/253
MB leprosy
778/1794
66/114
286/747
36/114
54/141
572/886
18/42
1996/2855
1201/2347
1773/6242
14/52
200/544
462/1058
18/177
9/37
7684/25954
18/19
25/107
8/42
41/54
107/368
117/6035
39/100
16/98
49/95
6/164
212/2220
11/170
46/442
6501/12256
Events,
1/3
5/131
3/34
PB leprosy
116/749
99/440
80/1041
13/130
17/81
29/80
14/52
6804/15041
300/2019
464/8145
6/48
4/43
194/1300
3/163
20/238
100.00
1.09
4.17
2.98
3.27
4.74
4.95
3.98
3.60
4.18
3.20
4.89
3.53
4.69
5.06
%
0.80
2.72
2.30
Weight
27.23
4.42
4.82
3.65
3.84
4.30
3.15
24.36
29.07
19.34
2.66
2.68
4.96
2.24
3.11
Favors PB leprosy  Favors MB Leprosy 
1.00522 192
NOTE: Weights are from random effects analysis
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Subtotal  (I-squared = .%, p = .)
Santos et al, 2015
ID
Study
Primary health care
Patel et al, 2016
Subtotal  (I-squared = 98.2%, p = 0.000)
Monteiro et al, 2013
Monteiro et al, 2015
General hospital
Subtotal  (I-squared = 0.0%, p = 0.693)
Subtotal  (I-squared = .%, p = .)
Kar et al, 2005
Health information system
Sethi et al, 2015
Specialized health center
2.43 (1.35, 4.36)
3.64 (1.82, 7.29)
1.03 (0.84, 1.27)
OR (95% CI)
2.31 (1.36, 3.92)
1.81 (0.60, 5.52)
3.64 (1.82, 7.29)
3.19 (2.57, 3.94)
2.44 (1.57, 3.81)
3.24 (1.27, 8.30)
2.81 (1.24, 6.36)
3.24 (1.27, 8.30)
410/1694
18/56
162/655
reaction
Leprosy
65/100
302/1457
18/56
140/802
76/155
Events,
14/26
11/55
14/26
947/7997
26/226
493/2043
reaction
leprosy
62/139
823/7344
26/226
330/5301
80/359
Events, No
18/68
18/220
18/68
100.00
15.71
19.66
Weight
%
17.29
39.28
15.71
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31.76
13.26
14.46
13.26
Favors No leprosy reaction  Favors Leprosy reaction 
1.12 8.3
NOTE: Weights are from random effects analysis
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Study
ID
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Kumar et al, 2012
Health information system
Subtotal  (I-squared = 75.9%, p = 0.041)
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Subtotal  (I-squared = 0.0%, p = 0.962)
Sethi et al, 2015
Ahmad et al, 2004
Subtotal  (I-squared = .%, p = .)
Specialized health center
Nardi et al, 2012
Subtotal  (I-squared = 0.0%, p = 0.452)
General hospital
2.94 (1.72, 5.02)
5.20 (4.26, 6.35)
1.84 (1.52, 2.24)
OR (95% CI)
1.86 (1.43, 2.41)
7.45 (2.97, 18.66)
1.59 (0.07, 36.24)
1.85 (1.58, 2.16)
0.24 (0.01, 4.74)
5.65 (2.28, 13.99)
1.92 (0.95, 3.86)
1.92 (0.95, 3.86)
5.29 (4.35, 6.43)
1456/2660
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201/977
Events,
Lepromatous
243/476
13/51
24/38
444/1453
0/3
24/35
25/52
25/52
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4253/9449
3689/6032
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Borderline
170/473
9/205
47/141
479/2982
30/80
17/61
29/89
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3698/6237
100.00
19.24
19.27
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Weight
18.89
12.49
15.35
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14.75
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.
.
.
.
Overall  (I-squared = 90.8%, p = 0.000)
Kumar et al, 2012
Santos et al, 2015
Monteiro et al, 2015
Nardi et al, 2012
Health information system
Sethi et al, 2015
Subtotal  (I-squared = .%, p = .)
Subtotal  (I-squared = .%, p = .)
Primary health care
General hospital
Zhang et al, 1993
Study
ID
Ahmad et al, 2004
Subtotal  (I-squared = .%, p = .)
Specialized health center
Subtotal  (I-squared = 61.8%, p = 0.106)
5.85 (3.56, 9.61)
(Excluded)
5.05 (3.86, 6.59)
6.89 (5.28, 9.01)
1.98 (0.87, 4.48)
(Excluded)
1.98 (0.87, 4.48)
10.77 (8.84, 13.12)
10.77 (8.84, 13.12)
OR (95% CI)
(Excluded)
. (., .)
5.90 (4.34, 8.01)
1456/2660
13/51
243/476
201/977
25/52
0/3
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15/47
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14.81 (3.21, 68.32)
(Excluded)
. (., .)
7.06 (5.21, 9.57)
12.80 (6.64, 24.67)
(Excluded)
14.81 (3.21, 68.32)
(Excluded)
20.56 (14.79, 28.59)
OR (95% CI)
1456/2660
444/1453
963/1117
25/52
0/3
24/38
243/476
950/1066
25/52
13/51
201/977
Lepromatous
Events,
137/4341
119/4265
16/41
2/34
0/1
0/1
73/567
16/41
.
2/34
0/0
46/3698
Indeterminate
Events,
100.00
62.12
25.44
12.44
0.00
0.00
31.23
25.44
0.00
12.44
0.00
30.90
Weight
%
Favors Indeterminate  Favors Lepromatous 
1.0146 68.3
